TY  - BOOK
AU  - Swain, Sandra M
TI  - Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study. []
SN  - 0167-6806
PY  - 2015///
KW  - *Breast Neoplasms/dt [Drug Therapy]
KW  - *Cyclophosphamide/ad [Administration & Dosage]
KW  - *Doxorubicin/ad [Administration & Dosage]
KW  - *Paclitaxel/ad [Administration & Dosage]
KW  - *Pyrimidines/ad [Administration & Dosage]
KW  - *Sulfonamides/ad [Administration & Dosage]
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms/pa [Pathology]
KW  - Cyclophosphamide/ae [Adverse Effects]
KW  - Doxorubicin/ae [Adverse Effects]
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Female
KW  - Fluorouracil/ad [Administration & Dosage]
KW  - Humans
KW  - Lymph Nodes/de [Drug Effects]
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Neoplasm Staging
KW  - Paclitaxel/ae [Adverse Effects]
KW  - Pyrimidines/ae [Adverse Effects]
KW  - Receptor, ErbB-2/ge [Genetics]
KW  - Sulfonamides/ae [Adverse Effects]
KW  - Washington Cancer Institute
KW  - Clinical Trial, Phase II
KW  - Journal Article
KW  - Research Support, Non-U.S. Gov't
N2  - This multicenter single-arm phase II study evaluated the addition of pazopanib to concurrent weekly paclitaxel following doxorubicin and cyclophosphamide as neoadjuvant therapy in human epidermal growth factor receptor (HER2)-negative locally advanced breast cancer (LABC). Patients with HER2-negative stage III breast cancer were treated with doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) for four cycles every 3 weeks followed by weekly paclitaxel 80 mg/m(2) on days 1, 8, and 15 every 28 days for four cycles concurrently with pazopanib 800 mg orally daily prior to surgery. Post-operatively, pazopanib was given daily for 6 months. The primary endpoint was pathologic complete response (pCR) in the breast and lymph nodes. Between July 2009 and March 2011, 101 patients with stage IIIA-C HER2-negative breast cancer were enrolled. The pCR rate in evaluable patients who initiated paclitaxel and pazopanib was 17 % (16/93). The pCR rate was 9 % (6/67) in hormone receptor-positive tumors and 38 % (10/26) in triple-negative tumors. Pre-operative pazopanib was completed in only 39 % of patients. The most frequent grade 3 and 4 adverse events during paclitaxel and pazopanib were neutropenia (27 %), diarrhea (5 %), ALT and AST elevations (each 5 %), and hypertension (5 %). Although the pCR rate of paclitaxel and pazopanib following AC chemotherapy given as neoadjuvant therapy in women with LABC met the pre-specified criteria for activity, there was substantial toxicity, which led to a high discontinuation rate of pazopanib. The combination does not appear to warrant further evaluation in the neoadjuvant setting for breast cancer
UR  - http://dx.doi.org/10.1007/s10549-014-3221-2
ER  -